How to Stifle Open Source Without Banning It
Benedikt Langer
6 Min. Read The sharpest argument against China’s top open AI comes from a man at OpenAI. Dean Ball, ...
Read Article
7 Min. read time
David Holz stands on stage and announces that soon, you’ll step into a shallow water bath and have your entire body scanned in just one minute. The man built Midjourney, a self-funded AI company that generates images. Now, he wants to reinvent medical imaging. The real question for decision-makers isn’t whether the device will deliver-it’s what this gamble reveals about the next phase of the AI economy, and how to separate hype from substance.
Key Takeaways
- A small player dares what the giants avoid: Midjourney is self-funded and venturing into a regulated, physical market. The big, externally funded labs have little incentive to follow suit.
- The lesson is focus, not size: Independence allows for long-term bets without quarterly pressures. For any digital leader, this is an argument against pure scaling strategies.
- Demos trump substance-on stage, at least: The prototype takes 20 minutes, not one. Those betting on trends must read this gap before investing.
Related:Muse Spark forces CIOs: Reassessing AI stack fundamentals / Europe’s AI future: Sovereignty belongs to those who control AI
What is Midjourney Medical? Midjourney Medical is a new division of the AI image generator Midjourney. Its first product is a full-body ultrasound scanner that operates without radiation or magnetic fields. The core technology comes from Butterfly Network, a publicly traded ultrasound specialist. This marks Midjourney’s first foray from software into physical hardware.
A Gamble No Frontier Lab Would Take
Let’s look at the players. The big AI labs are all chasing the same narrative: bigger models, more computing power, faster releases. Those reliant on external funding and under pressure to deliver every quarter have little incentive to take a leap into medical hardware. It’s slow, regulated, and expensive-hardly a selling point for the next funding round.
Midjourney, however, calls itself self-funded and profitable, which is precisely why it can afford to take this risk. Without external investors to answer to, it can play a long game, free from quarterly justifications. That’s the real strategic statement here-not the scanner itself.
The roadmap shows just how bold this gamble is.
The gap between a dozen test subjects and a billion monthly scans isn’t just about growth-it’s about building an entirely new infrastructure of regulation, distribution, and trust. That distance is what makes this gamble so intriguing for anyone making big digital decisions.
Key Takeaways for Digital Leaders
The first lesson is an uncomfortable one for scaling enthusiasts. Midjourney isn’t gaining its edge through size, but through independence. A CIO with their own budget and a clear mandate can back a risky initiative that a consensus-driven committee would have shot down in minutes. Focus and autonomy trump sheer resources here.
The second lesson is about direction. AI is stepping out of its software comfort zone and pushing into physical, regulated spaces. Those who see AI strategy purely as a question of models and tools are missing the bigger picture. Hardware, compliance, and liability are back on the agenda-and they’re far tougher to navigate than swapping an API.
Buy or Build?
The third lesson is a financial one. Even a self-funded company doesn’t build everything in-house. The license from Butterfly Network isn’t just a detail-it’s the foundation of the entire gamble.
68 Mio. €
Midjourney is paying Butterfly Network 68 million Euro over five years for ultrasound technology, according to a mandatory filing. Even independence doesn’t mean building everything from scratch.
Source: Butterfly Network, SEC Filing November 2025
For decision-makers, this means the build-or-buy question remains central, no matter how deep your pockets. From my own founder experience, I buy the components that every competitor can access. I only build what sets us apart.
How Do You Separate Hype from Substance?
Now for the part that matters most in day-to-day business. On stage, the talk is of a one-minute scan. In the lab, the process takes about 20 minutes, with around a dozen test subjects and no neural network called Midjourney. Both statements can be true. Only the second describes today’s actual device.
This gap isn’t nitpicking-it’s the core competency for anyone betting on tech trends. If you confuse a demo with a product, you’re budgeting for a future that doesn’t yet exist. The sober question is always: What’s measurable today, and what’s just a stage-lit promise?
In practice, a simple filter helps. For every trend claim, I separate two layers. The first is verifiable reality: how many real users, what metrics under real conditions, what independent validation. The second is the roadmap layer: what the company promises for the future. For the Midjourney scanner, the first layer shows a dozen test subjects and a 20-minute run. The second layer promises a billion scans and a one-second dream. Mix them up, and you’re buying a story, not a product.
This principle extends far beyond this single case. The same distinction protects you from every AI pitch selling pilot numbers as production-ready. The vision is almost always compelling. What counts is what already delivers today.
What Makes the Bet Hold
- Self-funding without quarterly pressure
- Proven ultrasound tech from Butterfly
- A real pain point: MRIs are expensive and scarce
What Could Sink It
- Regulatory approval and health data laws
- Image quality without AI reconstruction unclear
- Mass screening risks overdiagnosis
Counterarguments are valid: A demo *should* showcase a vision-that’s its purpose. The mistake starts when that vision becomes the basis for planning. A concrete action step for the next 90 days: Take an ongoing AI initiative in your organization and flag every metric sourced from a demo or vendor deck. What remains is your real foundation of facts.
Frequently Asked Questions
Why is an AI image generator moving into medicine?
Midjourney is self-funded and can afford to make a long-term, high-risk bet without having to answer to investors. Its new division is betting on a whole-body ultrasound scanner powered by technology from Butterfly Network.
What’s the key takeaway for decision-makers?
Independence and focus beat sheer size. A clear mandate can carry a high-risk initiative further than a large but consensus-driven budget.
Are the stated performance figures accurate?
The 60-second claim is an aspiration. Reports suggest the prototype currently takes around 20 minutes. Comparisons to MRI costs and speed reflect Midjourney’s ambitions-not certified product data.
What does this mean for your AI strategy?
AI is moving beyond software into hardware, certification, and liability. If you’re treating AI strategy as just a tool question, you’re underestimating the regulatory dimension.
How do you critically assess such announcements?
Separate every metric into what’s measurable today and what’s a statement of intent. Demo figures don’t belong in budget planning-verified prototype data does.
Read more on Digital Chiefs
Digital ChiefsCloud capacity is becoming scarce, CIOs need to plan nowDigital ChiefsBosch is scaling back to rebuildDigital ChiefsSmart Factory: Why Edge is Lagging Behind in the ProcessMore from the MBF Media Network
cloudmagazinMidjourney’s body scanner is a compute challenge mybusinessfutureShadow AI in SMEs: What covert usage reveals securitytodayRegulators target SMEs with the 72-hour reporting trapImage source: AI-generated (June 2026)